Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Henri Becquerel
With
U918 ( Inserm unit)
To determinate and to describe the clonal evolution, 30 DLBCL cases with available matched tumor DNA and plasma will be collected and analyzed by routinely applicable next generation sequencing (NGS) at the time of diagnosis, at mid treatment, at the end of treatment and at 12 months after diagnosis.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age up to 18 years old
With a diagnosis formally established of DLBCL or transformed straightaway follicular lymphoma or 3B grade follicular lymphoma or Burkitt-like lymphoma
Eligible to a treatment by immunochemotherapy like R-CHOP, R-ACVBP or R-CHOP like
First line of treatment
Being able to benefit from standard extension assessment ( Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and bone marrow biopsy with a bone marrow aspiration)
Written informed consent
Tumor biopsy used for diagnosis available
You may not be if
Patient who cannot receive polychemotherapy like R-CHOP, R-ACVBP, or R-CHOP like
Patient who cannot benefit from standard extension assessment and follow-up by with Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)
Pregnant or breast-feeding woman
Guardianship, curatorship
Patient who cannot follow the medical procedures of the study for geographic, social, psychological,linguistic or physical reasons
Clareo Health | Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS
